Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | ALPI | P09923 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | XIAP | P98170 | 1/20 | 0.49 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | PTPRA | P18433 | 1/20 | 0.46 |
| ▸ | PTPRB | P23467 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5288034 | 1.00 | NPC1 (0.53) | NPC1RAB9AMAPTLOXL2TP53 | |
| SCHEMBL11099516 | 1.00 | NPC1 (0.53) | NPC1RAB9AMAPTLOXL2TP53 | |
| SCHEMBL7909117 | 0.86 | NPC1 (0.58) | NPC1RAB9AMAPTLOXL2TP53 | |
| SCHEMBL11096618 | 0.84 | AKR1B1 (0.46) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL4484665 | 0.83 | RAB9A (0.54) | NPC1RAB9AMAPTLOXL2TP53 | |
| SCHEMBL6505533 | 0.83 | NPC1 (0.47) | NPC1RAB9AMAPTLOXL2TP53 | |
| SCHEMBL8298679 | 0.83 | NPC1 (0.47) | NPC1RAB9AMAPTLOXL2TP53 | |
| SCHEMBL30714783 | 0.82 | RAB9A (0.46) | NPC1RAB9AMAPTLOXL2TP53 | |
| SCHEMBL11099435 | 0.80 | MEN1 (0.50) | MAPTSMN1; SMN2LMNAPTPRAPTPRB | |
| SCHEMBL11100833 | 0.80 | GAA (0.45) | NPC1RAB9AMAPTTP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020230780-A1 | Ras INHIBITORY PEPTIDE | 一丸ファルコス株式会社 | 2020-11-19 | — | — | WO | claimed |
| US-7927579-B2 | Compounds comprising modified secondary ligand binding site for treatment and prevention of infections, diabetes, emphysema, viral, endocrine and cell proliferative disorders | ADVANCED PROTEOME THERAPEUTICS, INC (US) | 2011-04-19 | — | — | US | claimed |
| EP-1592801-B1 | Method for identifying activated polymer complexes for secondary site-specific modification of protein target groups. | ADVANCED PROTEOME THERAPEUTICS (US) | 2010-05-05 | — | — | EP | claimed |
| EP-1592801-A4 | TANDEM ANALYSES OF NONCOVALENTLY DRIVEN EFFECTORS FOR MODULATORY MAPPING OF ACTIVITIES OF PROTEIN SITES | ADVANCED PROTEOME THERAPEUTICS (US) | 2008-04-30 | — | — | EP | claimed |
| EP-1592801-A2 | TANDEM ANALYSES OF NONCOVALENTLY DRIVEN EFFECTORS FOR MODULATORY MAPPING OF ACTIVITIES OF PROTEIN SITES | Advanced Proteome Therapeutics Inc. (US) | 2005-11-09 | — | — | EP | claimed |
| US-20040176575-A1 | Tandem analyses of noncovalently driven effectors for modulatory mapping of activities of protein sites | ADVANCED PROTEOME THERAPEUTICS, INC. | 2004-09-09 | — | — | US | claimed |
| WO-2004066917-A2 | TANDEM ANALYSES OF NONCOVALENTLY DRIVEN EFFECTORS FOR MODULATORY MAPPING OF ACTIVITIES OF PROTEIN SITES | ADVANCED PROTEOME THERAPEUTICS, INC (US) | 2004-08-12 | — | — | WO | claimed |
| US-11858905-B1 | Cathepsin L inhibitors | BIOFRONT THERAPEUTICS (BEIJING) CO., LTD. (CN) | 2024-01-02 | — | — | US | disclosed |
| CN-116589425-A | Cathepsin L inhibitors | 百放英库医药科技(北京)有限公司 | 2023-08-15 | — | — | CN | disclosed |
| WO-2020230780-A1 | Ras INHIBITORY PEPTIDE | 一丸ファルコス株式会社 | 2020-11-19 | — | — | WO | disclosed |
| US-7927579-B2 | Compounds comprising modified secondary ligand binding site for treatment and prevention of infections, diabetes, emphysema, viral, endocrine and cell proliferative disorders | ADVANCED PROTEOME THERAPEUTICS, INC (US) | 2011-04-19 | — | — | US | disclosed |
| EP-1592801-B1 | Method for identifying activated polymer complexes for secondary site-specific modification of protein target groups. | ADVANCED PROTEOME THERAPEUTICS (US) | 2010-05-05 | — | — | EP | disclosed |
| EP-1592801-A4 | TANDEM ANALYSES OF NONCOVALENTLY DRIVEN EFFECTORS FOR MODULATORY MAPPING OF ACTIVITIES OF PROTEIN SITES | ADVANCED PROTEOME THERAPEUTICS (US) | 2008-04-30 | — | — | EP | disclosed |
| EP-1592801-A2 | TANDEM ANALYSES OF NONCOVALENTLY DRIVEN EFFECTORS FOR MODULATORY MAPPING OF ACTIVITIES OF PROTEIN SITES | Advanced Proteome Therapeutics Inc. (US) | 2005-11-09 | — | — | EP | disclosed |
| US-20040176575-A1 | Tandem analyses of noncovalently driven effectors for modulatory mapping of activities of protein sites | ADVANCED PROTEOME THERAPEUTICS, INC. | 2004-09-09 | — | — | US | disclosed |
| WO-2004066917-A2 | TANDEM ANALYSES OF NONCOVALENTLY DRIVEN EFFECTORS FOR MODULATORY MAPPING OF ACTIVITIES OF PROTEIN SITES | ADVANCED PROTEOME THERAPEUTICS, INC (US) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858905-B1 | Cathepsin L inhibitors | CTSV, CTSL, CTSB | NPC1 84/4885RAB9A 826/4885MAPT 1443/4885 |
| US-20040176575-A1 | Tandem analyses of noncovalently driven effectors for modulatory mapping of activities of protein sites | CHAMP1, STUB1, PTMS | NPC1 4360/4885RAB9A 2808/4885MAPT 3821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.